← Back

Pmv Pharmaceuticals Inc

PMV Pharmaceuticals, Inc. is a precision oncology company focused on discovering and developing small molecule therapies that target p53 mutations and other p53-related cancers in the United States. Its lead candidate, rezatapopt, is a selective structural corrector of p53 Y220C mutations and is in Phase 2 clinical trials for tumor-agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. It was incorporated in 2013 and is headquartered in Princeton, New Jersey.

Country
Price · split & dividend adjusted
News & notes moving PMVP
PMVP▲

PMV Pharma Appoints Philip Herman as Chief Commercial Officer

PMV Pharmaceuticals has appointed Philip Herman as Chief Commercial Officer to lead commercial strategy and launch preparation for rezatapopt, its first-in-class p53 reactivator, as the company plans to submit a New Drug Application for accelerated approval in platinum-resistant/refractory ovarian cancer in the first quarter of 2027. Herman brings over 24 years of experience in oncology and rare disease launches, having previously served as Chief Commercial and Portfolio Development Officer at Repare Therapeutics and CCO at Y-mAbs Therapeutics, where he led the launch of DANYELZA. PMV Pharma is completing enrollment in the PYNNACLE clinical trial and aims to bring the first therapy targeting mutant p53 to patients.
PMVP ▲
GlobeNewswire·10dRead more →
PMVP

PMV Pharma Prices $50M IPO at $1.21 Per Share

PMV Pharmaceuticals has priced its oversubscribed public offering, expected to raise about $50.8 million in gross proceeds. The offering includes 22.055 million shares of common stock and pre-funded warrants to purchase up to 19.9 million shares, along with warrants to purchase an aggregate of 41.955 million shares of common stock. The combined offering price is $1.21 per share and accompanying warrant, with pre-funded warrants priced at $1.20999 each and an exercise price of $0.00001 per share. PMV Pharma, a precision oncology company developing small-molecule therapies targeting p53, notes that TP53 mutations are found in approximately half of all cancers. The offering is expected to close on or about September 2.
PMVP
Seeking Alpha·17dRead more →
© 2026 MarketDXAsset